Deutsche Bank Research upgraded QIAGEN with an unchanged price target.
Deutsche Bank Research upgraded QIAGEN from “Hold” to “Buy” with an unchanged price target of $54. After his downgrade in January and the subsequent price slide on Friday, analyst Jan Koch is now returning to his buy recommendation for the diagnostics specialist. A takeover bonus has now been fully priced out. Investors could now concentrate on the operational business again. Although much depends on what happens later in 2026, this is the case for many companies in the industry. The QIAGEN assessment is unambitious.
The QIAGEN share temporarily gained 1.22 percent to 35.82 euros in XETRA trading on Friday.
/ag/e.g
Publication of the original study: Date not specified in study / Time not specified in study / CET
First distribution of the original study: March 13, 2026 / 05:01 / CET
———————-
dpa-AFX Broker – the trader news from dpa-AFX
———————-
FRANKFURT (dpa-AFX Broker)
Selected leverage products on QIAGEN
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on QIAGEN
The leverage must be between 2 and 20
Advertising
